Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More
Xconomy
APRIL 17, 2020
The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Alnylam had sold the drug’s development and commercialization rights seven years ago.
84 
Let's personalize your content